Thanks to Wasron,jfgw,Rhyd6,eyeball08,Wondergirly, for Donating to support the site
idpickering wrote:Bubblesofearth wrote:Shares up 2.5% as I write and have been my best performer since purchase over 10 years ago.
I'm a very happy shareholder
BoE
Agreed, and likewise. There is a temptation to trim my holdings tbh as they've become very overweight in my HYP. HYP chat is not for hereabouts though.
Ian.
yorkshirelad1 wrote:Dod101 wrote:[snip] but the dividend is still being held. Dod
The results (https://www.astrazeneca.com/media-centre/press-releases/2023/full-year-and-q4-2022-results.html) show a full year dividend held at $2.90. The results also note a full year dividend of 239.2 pence. That's compared to 210.1p last year. I make that +13.9% . Just saying.
Dod101 wrote:idpickering wrote:
Agreed, and likewise. There is a temptation to trim my holdings tbh as they've become very overweight in my HYP. HYP chat is not for hereabouts though.
Ian.
No but discussing trimming is surely acceptable. This is not the HYP Board! I trimmed on 3 January at £114.
Dod
scrumpyjack wrote:
Core eps excludes things like legal costs, aborted development costs, write offs etc all of which happen every year and are a normal part of being a pharmaceutical company and are cash costs in the long term. But all pharma companies focus on an adjusted or core figure which excludes them.
If you look at their balance sheet over the years the cash goes down and the borrowings go up. The SP is forward looking and the hope is that at some point the actual cash profits will be similar to the core profit, but that tomorrow never seems to come. I don't have any pharma shares (did have some AZN but sold some and gave the rest to the grandchildren) because, as a retired chartered accountant I have this old fashioned preference for companies that make actual cash profits which more than cover their dividends and do not have large special write offs every year.
Bubblesofearth wrote:scrumpyjack wrote:
Core eps excludes things like legal costs, aborted development costs, write offs etc all of which happen every year and are a normal part of being a pharmaceutical company and are cash costs in the long term. But all pharma companies focus on an adjusted or core figure which excludes them.
If you look at their balance sheet over the years the cash goes down and the borrowings go up. The SP is forward looking and the hope is that at some point the actual cash profits will be similar to the core profit, but that tomorrow never seems to come. I don't have any pharma shares (did have some AZN but sold some and gave the rest to the grandchildren) because, as a retired chartered accountant I have this old fashioned preference for companies that make actual cash profits which more than cover their dividends and do not have large special write offs every year.
There are plus and minus points for all companies but at any given time these are well known to the market. If you can find some with good divi cover, excellent growth prospects, no regulatory issues, no large annual write-offs and sitting on an attractive P/E and yield then congratulations and please share!
The fact remains that AZN have been an incredible profitable share to own for the last however many years.
BoE
scrumpyjack wrote:
There were many years when they were a very bad investment, with patents expiring and seemingly very little in the pipeline. Eventually Pfizer bid for them. Pharma have the big problem that they have to work very hard to discover and develop new drugs. If they succeed, they make hay for a few years, but then the patents expire and they have to start all over again! I had a reasonably large holding which I sold in 2013 as they had been such a poor performer for so long. For the moment things look good for them because their development pipeline looks very promising. They may well continue to be an excellent investment but history shows they are cyclical and have to keep reinventing new wheels.
I would have done better continuing to hold them, but did very well in builders and miners (who do make real profits and cash without exceptional items every year or having to fiddle their presentation of results). They too are cyclical, obviously.
All this illustrates is why one should have diversification in one’s portfolio.
Bouleversee wrote:
I hadn't realised Soriot was earning £14m. In his shoes I would feel very uncomfortable about taking so much when payments to shareholders were being restricted.
Bubblesofearth wrote:Bouleversee wrote:
I hadn't realised Soriot was earning £14m. In his shoes I would feel very uncomfortable about taking so much when payments to shareholders were being restricted.
Are you talking about dividend payments? This seems to be a peculiar obsession hereabouts and not one that is widely observed outside the UK. Surely it's more important that companies with growth potential reinvest as well as pay out? The growth potential for healthcare is massive given ageing populations in many developed countries and the still large number of unmet needs.
Personally, as a shareholder, I would not want AZN to be paying higher divis just now.
BoE
Bouleversee wrote:However, pension funds and pensioners do generally need a reasonable income from their investments
Bouleversee wrote:I hadn't realised Soriot was earning £14m. In his shoes I would feel very uncomfortable about taking so much when payments to shareholders were being restricted.
When a team reaches the quarter finals, how much is that down to the manager and how much to the team? C.ADrunkenMarcus wrote:OTOH, he has delivered.
csearle wrote:When a team reaches the quarter finals, how much is that down to the manager and how much to the team? C.ADrunkenMarcus wrote:OTOH, he has delivered.
yorkshirelad1 wrote:I've just been looking at the AZN 2022 AR recently published (https://www.astrazeneca.com/investor-relations/annual-reports.html), esp in relation to the dividends, and it's the most confusing piece of work, and you have to look very carefully
AstraZeneca and KYM Biosciences Inc.i have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally.
yorkshirelad1 wrote:I've just been looking at the AZN 2022 AR recently published (https://www.astrazeneca.com/investor-relations/annual-reports.html), esp in relation to the dividends, and it's the most confusing piece of work, and you have to look very carefully
Right up at the front on page 4 and as part of the Chairman's statement, it says dividend 2.87 to 2.9
On page 181 you have
On page 211 you have
and these latter two which say 2.80 to 2.90
How is it possible to put such contradictory information in an annual report without clarification. And what should one use as a yardstick when comparing annual dividends. I know it's probably mostly down to the calendar, but really? My head hurts....
I suppose either way, it's gone up in cents (and gone up in GBP 210.1p->239.2p (+13.9%) courtesy of the exchange rate)
AstraZeneca announced today the successful completion of the acquisition of CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
Baxdrostat represents a potentially leading next-generation ASI as it is highly selective for aldosterone synthase and spares the cortisol pathway in humans1. The opportunity also brings the potential for combination with Farxiga and complements AstraZeneca's strategy to provide added benefit across cardiorenal diseases, where there is a high unmet medical need.
The acquisition was completed through a tender offer to purchase all outstanding shares of CinCor for approximately $1.3bn upfront. As part of the transaction, AstraZeneca acquired the cash and marketable securities on CinCor's balance sheet, which totalled approximately $500 million as of the closing, excluding transaction-related expenses. Under the terms of the agreement, CinCor shareholders also received a non-tradable contingent value right, payable upon a specified regulatory submission of a baxdrostat product. Combined, the upfront and contingent value payments represent, if achieved, a transaction value of approximately $1.8bn. As of the expiration of the tender offer, 39,580,275 shares of CinCor were validly tendered and not validly withdrawn from the tender offer, representing approximately 86.3% of the outstanding shares of common stock of CinCor, and such shares have been accepted for payment in accordance with the terms of the tender offer. CinCor's shares will be delisted from the Nasdaq Stock Market, and CinCor will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.
Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.
Return to “Company Share news (LSE Main Market)”
Users browsing this forum: Google [Bot] and 50 guests